Artelo Biosciences Stock Working Capital
| ARTL Stock | USD 10.20 1.66 14.00% |
Fundamental analysis of Artelo Biosciences allows traders to better anticipate movements in Artelo Biosciences' stock price by examining its financial health and performance throughout various phases of its business cycle.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Artelo Biosciences Company Working Capital Analysis
Artelo Biosciences' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Artelo Biosciences Working Capital | 785 K |
Most of Artelo Biosciences' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Artelo Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
In accordance with the company's disclosures, Artelo Biosciences has a Working Capital of 785 K. This is 99.82% lower than that of the Pharmaceuticals sector and 99.85% lower than that of the Health Care industry. The working capital for all United States stocks is 99.95% higher than that of the company.
Artelo Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Artelo Biosciences' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Artelo Biosciences could also be used in its relative valuation, which is a method of valuing Artelo Biosciences by comparing valuation metrics of similar companies.Artelo Biosciences is currently under evaluation in working capital category among its peers.
Artelo Fundamentals
| Return On Equity | -1.91 | ||||
| Return On Asset | -0.89 | ||||
| Current Valuation | 7.67 M | ||||
| Shares Outstanding | 700.37 K | ||||
| Shares Owned By Insiders | 0.63 % | ||||
| Shares Owned By Institutions | 2.04 % | ||||
| Number Of Shares Shorted | 30.59 K | ||||
| Price To Earning | 16.31 X | ||||
| Price To Book | 12.76 X | ||||
| EBITDA | (7.44 M) | ||||
| Net Income | (9.83 M) | ||||
| Cash And Equivalents | 21.32 M | ||||
| Cash Per Share | 7.51 X | ||||
| Total Debt | 1.84 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 42.28 X | ||||
| Book Value Per Share | 1.19 X | ||||
| Cash Flow From Operations | (8.35 M) | ||||
| Short Ratio | 0.02 X | ||||
| Earnings Per Share | (17.94) X | ||||
| Target Price | 20.0 | ||||
| Beta | 1.34 | ||||
| Market Capitalization | 8.31 M | ||||
| Total Asset | 4.7 M | ||||
| Retained Earnings | (50.14 M) | ||||
| Working Capital | 785 K | ||||
| Current Asset | 99.89 M | ||||
| Current Liabilities | 23.67 M | ||||
| Net Asset | 4.7 M |
About Artelo Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Artelo Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Artelo Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Artelo Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Artelo Biosciences Piotroski F Score and Artelo Biosciences Altman Z Score analysis. For more information on how to buy Artelo Stock please use our How to buy in Artelo Stock guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Artelo Biosciences. If investors know Artelo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Artelo Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Artelo Biosciences is measured differently than its book value, which is the value of Artelo that is recorded on the company's balance sheet. Investors also form their own opinion of Artelo Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Artelo Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Artelo Biosciences' market value can be influenced by many factors that don't directly affect Artelo Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Artelo Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Artelo Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Artelo Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.